854778-10-2

Basic information

• Product Name: ethyl 2-(4-cyanophenyl)-2,2-difluoroacetate
• Synonyms: ethyl 2-(4-cyanophenyl)-2,2-difluoroacetate
• CAS NO: 854778-10-2
• Molecular Formula: C₁₁H₉F₂NO₂
• Molecular Weight: 225.1914664
• Mol File: 854778-10-2.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ethyl 2-(4-cyanophenyl)-2,2-difluoroacetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(4-cyanophenyl)-2,2-difluoroacetate(854778-10-2)
• EPA Substance Registry System: ethyl 2-(4-cyanophenyl)-2,2-difluoroacetate(854778-10-2)

Safety Data

• Hazardous Substances Data: 854778-10-2(Hazardous Substances Data)

Upstream product

• 3058-39-7 4-iodobenzonitrile 
• 1308915-11-8 ethyl 2,2-difluoro-2-(triethylsilyl)acetate 
• 205865-67-4 α-(trimethylsilyl)difluoroacetic acid ethyl ester 
• 667-27-6 Ethyl bromodifluoroacetate 
• 126747-14-6 4-cyanophenylboronic acid 
• 383-62-0 ethyl 2-chloro-2,2-difluoroacetate 
• 873-74-5 4-Aminobenzonitrile 
• 66107-32-2 4-cyanophenyl trifluoromethanesulfonate 

Downstream Products

• 936352-93-1 difluoro-(4-formylphenyl)acetic acid ethyl ester 
• 854767-40-1 ethyl {4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amino)methyl]phenyl}(difluoro)acetate 
• 1261358-84-2 2-(4-cyanophenyl)-2,2-difluoro-acetic acid 
• 55805-10-2 4-cyano-1-difluoromethylbenzene 

Relevant articles and documents

Silver-catalyzed decarboxylative radical allylation of α,α-difluoroarylacetic acids for the construction of CF2-allyl bonds

An efficient silver-catalyzed method of decarboxylative radical allylation of α,α-difluoroarylacetic acids to build CF2-allyl bonds has been developed. Using allylsulfone as an allyl donor, α,α-difluorine substituted arylacetic acids bearing various functional groups are successfully allylated to access a series of 3-(α,α-difluorobenzyl)-1-propylene compounds in moderate to excellent yields in aqueous CH3CN solution under the mild conditions. Experimental studies disclosed that the α-fluorine substitution of arylacetic acid has a great influence on free radical activity and reactivity.

Synthetic method of aromatic ring group or aromatic heterocyclic tetrazole

The synthetic method comprises the following steps: (1) reacting 1.0 eq of ArI or HArI with 1.2 eq of ethyl 2, 2-difluoroacetate in the presence of DMSO as a solvent and 4.0 eq of Cu under the protection of nitrogen at 30 DEG C and 50 DEG C, and purifying to obtain a first intermediate compound; (2) dissolving 1.0 eq of the first intermediate compound in a mixed solvent of THF and water, adding 2.0 eq of LiOH, reacting at room temperature for 2 hours, spin-drying the solvent, adding HCl until the pH value is equal to 3, and filtering to obtain a second intermediate compound; and (3) reacting 1.0 eq of the second intermediate compound with 2.0 eq of diphenyl azide phosphate in the presence of 2.5 eq of triethylamine by taking tert-butyl alcohol as a solvent to generate aromatic ring group or aromatic heterocyclic tetrazole. The invention provides a novel synthetic method of aromatic ring group or aromatic heterocyclic tetrazole, wherein a target compound can be more conveniently obtained, and reagents participating in the reaction are low in toxicity, mild in reaction condition, simple and safe in aftertreatment, good in product quality and suitable for large-scale production.

1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2', R3, R4, R5, R6, and R7 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.